Monte Carlo Computation of Dose-Volume Histograms in Structures at Risk of an Eye Irradiated with Heterogeneous Ruthenium-106 Plaques.
Brachytherapy
Dose-volume histogram
Dosimetry
Eye plaques
Monte Carlo
PENELOPE
Ruthenium
Treatment planning
β-Emitter
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
02
01
2020
accepted:
18
04
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
31
10
2020
Statut:
ppublish
Résumé
The aim of this work is to compare Monte Carlo simulated absorbed dose distributions obtained from The generic CCA and CCB, with a homogeneous emitter map, and the specific CCA1364 and CCB1256 For the cornea, the CCA with the equatorial placement yields the lowest absorbed dose rate while for the CCA1364 in the same placement the absorbed dose rate is 33% higher. The CCB1256 with the hot spot oriented towards the cornea yields the maximum dose rate per unit of activity while it is 44% lower for the CCB. Dose calculations based on a homogeneous distribution of the emitter substance yield the lowest absorbed dose in the analyzed structures for all plaque placements. Treatment planning based on such calculations may result in an overdose of the structures at risk.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
The aim of this work is to compare Monte Carlo simulated absorbed dose distributions obtained from
METHODS
METHODS
The generic CCA and CCB, with a homogeneous emitter map, and the specific CCA1364 and CCB1256
RESULTS
RESULTS
For the cornea, the CCA with the equatorial placement yields the lowest absorbed dose rate while for the CCA1364 in the same placement the absorbed dose rate is 33% higher. The CCB1256 with the hot spot oriented towards the cornea yields the maximum dose rate per unit of activity while it is 44% lower for the CCB.
CONCLUSIONS
CONCLUSIONS
Dose calculations based on a homogeneous distribution of the emitter substance yield the lowest absorbed dose in the analyzed structures for all plaque placements. Treatment planning based on such calculations may result in an overdose of the structures at risk.
Identifiants
pubmed: 33123529
doi: 10.1159/000508113
pii: oop-0006-0353
pmc: PMC7574611
doi:
Types de publication
Journal Article
Langues
eng
Pagination
353-359Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Med Phys. 2009 Oct;36(10):4634-43
pubmed: 19928095
Med Phys. 2007 Dec;34(12):4818-53
pubmed: 18196810
Ocul Oncol Pathol. 2014 Oct;1(1):2-12
pubmed: 27175356
Med Phys. 2001 Jul;28(7):1373-84
pubmed: 11488568
Klin Monbl Augenheilkd. 1966;148(5):682-99
pubmed: 5996539
Strahlenther Onkol. 2011 Aug;187(8):492-8
pubmed: 21789740
Surv Ophthalmol. 2009 Sep-Oct;54(5):545-68
pubmed: 19682622
Ophthalmology. 2005 May;112(5):834-40
pubmed: 15878063
Radiother Oncol. 1998 Nov;49(2):191-6
pubmed: 10052886
Strahlenther Onkol. 2013 Jan;189(1):68-73
pubmed: 23161122
Radiother Oncol. 2012 Aug;104(2):267-8
pubmed: 22857802
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1330-7
pubmed: 22245192
Surv Ophthalmol. 1974 Sep-Oct;19(2):85-100
pubmed: 4612808
Phys Med Biol. 2007 Nov 7;52(21):6475-83
pubmed: 17951856
Med Phys. 2011 Nov;38(11):5887-95
pubmed: 22047353
Br J Ophthalmol. 1986 Nov;70(11):844-51
pubmed: 3790487
Med Phys. 2003 Jun;30(6):1219-28
pubmed: 12852546
Med Phys. 1983 May-Jun;10(3):275-83
pubmed: 6308407
Strahlenther Onkol. 2007 Oct;183(10):571-5
pubmed: 17896089
Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3380-6
pubmed: 15452039
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):544-55
pubmed: 12738332
Med Phys. 2008 Jan;35(1):206-15
pubmed: 18293576
Med Phys. 1997 Feb;24(2):211-3
pubmed: 9048360
Radiat Prot Dosimetry. 2005;116(1-4 Pt 2):454-60
pubmed: 16604677
Med Phys. 1992 May-Jun;19(3):691-4
pubmed: 1508109
Radiother Oncol. 1993 Oct;29(1):33-8
pubmed: 8295985
Ocul Oncol Pathol. 2019 Jun;5(4):276-283
pubmed: 31367591
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763
Strahlenther Onkol. 1992 Feb;168(2):61-5
pubmed: 1542847
Med Phys. 2013 Oct;40(10):101705
pubmed: 24089895
Radiother Oncol. 1999 Nov;53(2):133-7
pubmed: 10665790
Med Phys. 2001 Jul;28(7):1385-96
pubmed: 11488569
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1212-21
pubmed: 16682139
Ocul Oncol Pathol. 2017 Sep;3(3):204-209
pubmed: 29071271
Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1533-40
pubmed: 22354369